Pharmacokinetics, safety, and tolerability of BMS-986263, a lipid nanoparticle containing HSP47 siRNA, in participants with severe hepatic impairment

MLA

Giridhar Tirucherai, et al. “Pharmacokinetics, Safety, and Tolerability of BMS-986263, a Lipid Nanoparticle Containing HSP47 SiRNA, in Participants with Severe Hepatic Impairment.” Journal of Hepatology, vol. 77, July 2022, p. S687. EBSCOhost, https://doi.org/10.1016/s0168-8278(22)01692-0.

APA

Giridhar Tirucherai, Eric Lawitz, Claudia De Oliveira, Hisham Qosa, & Edgar Charles. (2022). Pharmacokinetics, safety, and tolerability of BMS-986263, a lipid nanoparticle containing HSP47 siRNA, in participants with severe hepatic impairment. Journal of Hepatology, 77, S687. https://doi.org/10.1016/s0168-8278(22)01692-0

Chicago

Giridhar Tirucherai, Eric Lawitz, Claudia De Oliveira, Hisham Qosa, and Edgar Charles. 2022. “Pharmacokinetics, Safety, and Tolerability of BMS-986263, a Lipid Nanoparticle Containing HSP47 SiRNA, in Participants with Severe Hepatic Impairment.” Journal of Hepatology 77 (July): S687. doi:10.1016/s0168-8278(22)01692-0.